Drug Profile
Research programme: anticancer antibodies - Affitech AS
Alternative Names: CBAS 1; CBAS 2; CBAS 4/5; CBAS 6Latest Information Update: 18 Jan 2011
Price :
$50
*
At a glance
- Originator Affitech AS
- Developer Affitech A/S
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer